55432-07-0

Usage

InChI:InChI=1/C17H12ClN3/c18-15-8-6-13(7-9-15)17-14(10-11-19)12-21(20-17)16-4-2-1-3-5-16/h1-9,12H,10H2

Upstream product

• 36640-39-8 4-hydroxy-methyl-1-phenyl-3-(p-chlorophenyl)-pyrazol 
• 36663-00-0 1-phenyl-3-(4-chlorophenyl)-4-pyrazolecarboxaldehyde 
• 143-33-9 sodium cyanide 
• 55432-06-9 4-(chloromethyl)-3-(4-chlorophenyl)-1-phenyl-1H-pyrazole 

Downstream Products

• 53808-88-1 lonazolac 

Relevant academic research and scientific papers

Synthesis and physico-chemical properties of lonazolac-Ca, a new anti-inflammatory/antirheumatic agent

Calcium-[3-(p-chlorophenyl)-1-phenylpyrazole-4]-acetate (Lonazolac-Ca, active principle of Irritren) is a new anti-inflammatory/antirheumatic agent whose synthesis and physico-chemical properties are described. The physical parameters measured (pKa, partition coefficient P, saturation concentration c(s), surface activity, protein binding) are held against the corresponding values of indometacin, diclofenac, and phenylbutazone. The size of the permeability coefficient P(m) of the passive transport through artificial phospholipid collodion membranens as well as the invasion curves calculated from P(m) indicate a good absorption of lonazolac in man.

Pyrazol-4-acetic acid compounds

Pyrazol-4-acetic acid compounds, such as substituted pyrazol-4-acetic acid, its esters, amides, nitriles and their pharamaceutically acceptable salts and method for the preparation of these compounds are disclosed. The novel compounds are useful analgesics, anti-inflammatory, and antipyretics.

1,3-Diaryl-pyrazol-4-acrylic acid and derivatives

The invention concerns diarylpyrazole lower alkanoic acids and derivatives which are pharmacologically efficacious as anti-inflammatory agents. The said compounds can be represented by the formula STR1 in which one of D, E, F and G represents hydrogen, one is a lower aliphatic acid radical or derivative thereof and the remaining two of D, E, F and G are aryl or heteroaryl radicals.